Vitreopapillary traction in proliferative diabetic vitreoretinopathy [ssee comments].
OBJECTIVE
To present the clinical profile of a new entity in advanced proliferative diabetic vitreoretinopathy (PDVR). Mechanisms of vision loss due to vitreopapillary traction on the nasal optic disc are described, followed by an introduction of methods for prevention and treatment in such cases.


METHODS
17 patients with PDVR and traction on the nasal side of the optic disc, pallor of the optic nerve head, and reduced visual acuity were included in the study. Six patients were observed retrospectively and 11 patients prospectively before and after pars plana vitrectomy. Pre- and postoperative examinations included visual acuity, Goldmann's visual field, fluorescein angiography, and measurements of visual evoked potentials (VEP).


RESULTS
During a postoperative follow up period of 3 to 24.5 months (mean 14.5 months) an improvement in optic disc appearance combined with an increased visual acuity (mean increase in VA = 0.171) was observed in 15/17 (88.3%) patients. In addition, 8/17 (47%) of these patients showed higher VEP amplitudes (mean 3.83 microV), and eight (6/8 of the same patients as VEP amplitudes) patients showed a reduction of latency (mean reduction 22.25 ms) during VEP assessment.


CONCLUSIONS
These results suggest that vitreopapillary traction may damage the anterior optic nerve, via decreased axoplasmatic flow in the optic nerve fibres and/or mechanical reduction of perfusion in the posterior ciliary arteries. The effects of each mechanism appear to be reversible, but in the long term might lead to irreversible optic nerve atrophy. Therefore, in patients with vitreopapillary traction, early vitrectomy should be considered as a method to prevent optic neuropathy.
Kroll
P
P
Department of Ophthalmology, Philipps-University Marburg, Germany.
Wiegand
W
W
Schmidt
J
J
D000328:Adult; D000368:Aged; D003930:Diabetic Retinopathy / Q000150:complications* / Q000503:physiopathology / Q000601:surgery; D005074:Evoked Potentials, Visual; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009896:Optic Atrophy / Q000209:etiology* / Q000517:prevention & control; D011446:Prospective Studies; D012189:Retrospective Studies; D014792:Visual Acuity; D014821:Vitrectomy